Abstract 153P
Background
Long non-coding RNAs (LncRNAs) widely involved in various processes in cancers. Exosomes are important elements in tumor microenvironment, and usually transmit miRNAs or LncRNAs in cancer cells. Rapid progression of residual hepatocellular carcinoma after insufficient radiofrequency ablation has been confirmed, however, the role of exosomes in the underlying mechanism has never been unmasked.
Methods
The expression of LINC00174 was modified in the Huh7 and Huh7-H cell lines respectively. Western blot was used to examine the level of the exosomal protein marker. Transwell assay and western blot were used to evaluate the migration function of the HCC cells. qRT-PCR and western blot were used to examine the expression of LINC00174 level in the exosomes derived from the modified HCC cells. Online UCSC and JASPAR were used to predict the LINC00174 transcription. ChIP and a luciferase reporter assay were used to validate the positive regulation of MYC on LINC00174 transcription.
Results
LINC00174 was upregulated in both the cells and exosomes of cells. LINC00174 affected HCC cell migration and EMT via ERK and JNK pathways. The changes of c-JUN and p-c-JUN level in HCC cells treated with exosomes containing different level of LINC00174. JASPAR revealed the binding motif of c-JUN protein on the promoter region of its targets. ChIP and luciferase reporter assay validated that c-JUN was a positive regulator of MYCBP transcription. Exosomal LINC00174 activated Ras-regulated ERK and JNK pathways to enhance c-JUN expression and phosphorylation, and therefore upregulated MYCBP to strengthen MYC transcriptional activity, finally resulting in accelerated HCC progression.
Conclusions
Exosomal LINC00174 facilitates EMT via ERK-JNK/c-JUN/MYCBP/c-MYC signaling, providing a new way for the HCC patients unfortunately received the insufficient RFA.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhe jiang Cancer Hospital.
Funding
National Natural Science Funds of China (Grant number: 81702371).
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract